Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 154 от 240

Предстои набиране Фаза 1/2

Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy

Carbon Monoxide Poisoning Carbon Monoxide Intoxication Carbon Monoxide Encephalopathy Carbon Monoxide-induced Parkinsonism

Hyperbaric Oxygen Therapy (HBO) is routine treatment of carbon monoxide (CO) poisoning to prevent delayed neurological sequelae. This study looking to see if neurologic outcomes are improved with the addition of dexamethasone. CO poisoning can initiate a free radical mediated process that can instigate a demyelinating process resulting in long term neurological sequelae in some, but not all patients. In other demyelinating disorders, steroids are a part of first line treatment. HBO is already used for acute CO poisoning, so this pilot study will try to ascertain if the addition of steroids in concert with each hyperbaric oxygen session will yield improved outcomes.

Начало: 01.07.2026 Край: 01.01.2028 Възраст: от 19 г.

United States University of Nebraska NCT06574048

Предстои набиране Ранна Фаза 1

MCE Molecular Imaging for ICI Myocarditis

Immune Checkpoint Inhibitor Myocarditis

Inflammation of the heart (myocarditis) is a serious condition that can cause heart failure, abnormal heart rhythms, cardiac arrest, and death. A new class of medications used for cancer called immune checkpoint inhibitors (ICI) work by increasing the body's inflammmation response, but can have a side effect of causing inflammation of the heart (ICI myocarditis). Rapid diagnosis of this condition is key to reversing it. The purpose of this study is to determine whether ICI myocarditis can be diagnosed using a new form of ultrasound imaging of the heart (echocardiography) that uses a contrast agent that is targeted to inflammation (Sonazoid).

Начало: 01.07.2026 Край: 01.07.2030 Възраст: от 18 г.

United States University of Virginia NCT07538544

Предстои набиране

Self-monitoring of Hearing Aids Using Artificial Intelligence

Hearing Loss

This project investigates how self-monitoring of hearing aids through an AI-based mobile app can complement physical and digital healthcare visits. The aim is to increase patient involvement in rehabilitation, enable hearing aid adjustments in everyday sound environments, and improve access to hearing care.

Начало: 01.07.2026 Край: 01.08.2028 Възраст: от 18 г.

Sodra Alvsborgs Hospital NCT07255586

Предстои набиране Фаза 1

ENGAGE-TBI Feasibility Study

TBI (Traumatic Brain Injury)

This study will first evaluate the feasibility of delivering the ENGAGE-TBI intervention in a community setting with adults with TBI.

Начало: 01.07.2026 Край: 01.04.2028 Възраст: от 18 г.

United States Washington University School of Medicine NCT07549997

Предстои набиране

Prognostication of Recovery in Early Disorders of Consciousness Study

Disorders of Consciousness Due to Severe Brain Injury

By collecting multimodal metrics (e.g., clinical factors, neuroimaging, and EEG) in the early phase of severe brain injury (i.e., during the acute hospitalization when a patient has impaired consciousness), and measuring the patients' recovery of consciousness, function, and quality of life in the late phase (at 6 months following the brain injury), we aim to construct an algorithm that synthesizes the results of these metrics to help predict recovery.

Начало: 01.07.2026 Край: 30.06.2032 Възраст: от 18 г.

Massachusetts General Hospital NCT04692922

Предстои набиране Фаза 2

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

NSCLC NSCLC (Advanced Non-small Cell Lung Cancer)

This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited. Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune checkpoint inhibitors. Ivonescimab targets both PD-1 and VEGF pathways, potentially enhancing antitumor immune responses and inhibiting tumor angiogenesis. The trial aims to evaluate the objective response rate (ORR) according to RECIST v1.1 criteria. The combination therapy is expected to offer a novel and effective treatment strategy for patients with relapsed NSCLC, addressing a significant unmet medical need.

Начало: 01.07.2026 Край: 31.07.2029 Възраст: от 18 г.

Switzerland Swiss Cancer Institute NCT07158489

Предстои набиране Фаза 3

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Talaromycosis

LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions: 1. Is induction therapy using a single 10 mg\\/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)? 2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone? 3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?

Начало: 01.07.2026 Край: 01.07.2031 Възраст: от 18 г.

United States, Vietnam Duke University NCT06525389

Предстои набиране

Enlace Familiar: Supporting the Mental Health of Latino Adolescents

Mental Health

The goal of this clinical trial is to pilot and evaluate Enlace Familiar, a culturally responsive intervention designed to support Latino adolescents in discussing their mental health needs with caregivers or other trusted adults. The study will examine the feasibility and acceptability of the intervention and examine its potential impact on mental health communication among Latino adolescents ages 14-18 experiencing mental health concerns. Participants will be randomized into two groups, with 32 adolescents assigned to the Enlace Familiar intervention and 32 adolescents assigned to a control condition. The intervention will be implemented in partnership with community health workers (CHWs), who will serve as culturally relevant facilitators. The main questions this study aims to answer are: 1. Is Enlace Familiar feasible and acceptable for Latino adolescents when delivered by CHWs? 2. Does participation in Enlace Familiar improve adolescents' discussions of mental health needs with caregivers or other trusted adults? Participants will: * Complete baseline assessments related to mental health communication, attitudes toward mental health, mental health literacy, and engagement in mental health services. * Participate in the Enlace Familiar intervention, delivered by trained CHWs. * Complete follow-up assessments to evaluate changes in primary and secondary outcomes. * Participate in qualitative interviews or feedback activities to provide information about the acceptability and perceived usefulness of the intervention. Researchers will use a mixed methods design to evaluate intervention feasibility and acceptability and to explore preliminary changes in adolescent mental health communication following participation in the intervention.

Начало: 01.07.2026 Край: 01.01.2029 Възраст: 14–18 г.

United States University of Michigan NCT07547631

Предстои набиране

In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy

Endonasal Surgery Endoscopic Sinus Surgery Olfactory Dysfunction

This research is being done to better characterize the part of the nose that helps us smell. Currently, the only ways to study smell loss mostly rely on how people report it, rather than being able to see the underlying structures directly. In this study, we will use a special microscope (Confocal Laser Endomicroscopy (CLE)), originally developed for brain tissue, to look at the part of the nose that helps to detects smell. We hope to identify the tiny structures in that area and see how they might be different in people who have smell loss compared to those who do not.

Начало: 01.07.2026 Край: 31.07.2027 Възраст: от 18 г.

United States Dartmouth-Hitchcock Medical Center NCT07546617

Предстои набиране

Adapting the Stanford Obstetric Recovery Checklist in Postpartum Women to a Digital Health Platform: A Feasibility Study

Childbirth Problems

Explore patient experiences engaging with a digital tool (app- and web-based) to support postpartum recovery. Postpartum recovery involves physical, emotional, and social changes, and many patients report unmet needs for timely guidance and reassurance. Digital health applications may provide scalable support by collecting patient-reported wellbeing data and delivering tailored education and self-management guidance. However, patient experience, acceptability, perceived usefulness require evaluation to inform implementation and improvements. Primary objective • To evaluate patient experience using the postpartum recovery app, including acceptability, usability, and perceived usefulness for the first 12 weeks postpartum. Secondary objectives * To characterize how patients engage with app content over time. * To gather patient recommendations for content and wording. * To evaluate patient engagement with the app over first 12 weeks postpartum (frequency and duration of use).

Начало: 01.07.2026 Край: 01.07.2027 Възраст: от 18 г.

United States Stanford University NCT07408557

Предстои набиране

Foot Reflexology in Neonates With Hypoxic-Ischemic Encephalopathy

Effect of Reflexology Hypoxic-Ischemic Encephalopathy, Neonatal Foot Reflexology Therapeutic Hypothermia

This randomized controlled trial aims to evaluate the effect of foot reflexology on comfort levels and physiological parameters in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. Neonates in the intervention group will receive standardized foot reflexology sessions in addition to routine care, while the control group will receive routine care alone. Comfort will be assessed using the COMFORTneo scale, and physiological parameters will be monitored throughout the intervention period.

Начало: 01.07.2026 Край: 01.03.2027 Възраст: 30–3 г.

Turkey (Türkiye) Istanbul Nisantasi University NCT07549789

Предстои набиране Фаза 4

Varenicline for Smoking Reduction in Veterans Not Ready To Quit

Veterans Tobacco Use Disorder Cigarette Smoking Tobacco Dependence

In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.

Начало: 01.07.2026 Край: 28.06.2030 Възраст: от 21 г.

United States VA Office of Research and Development NCT06966362

Предстои набиране Фаза 2

Oritavancin for Treatment of Serious Cardiac Infections

Infective Endocarditis Cardiac Device Infection Gram-positive Bacterial Infections

Cardiac infections, including infective endocarditis and cardiovascular implantable electronic device infections, are associated with substantial morbidity and mortality and are commonly caused by gram-positive bacteria. Standard management typically requires prolonged courses of intravenous antibiotics and extended hospitalisation, which are costly, burdensome, and associated with complications related to long-term vascular access. People who inject drugs are disproportionately affected and often experience stigma, barriers to care, and poorer outcomes. Long-acting lipoglycopeptides such as oritavancin maintain therapeutic serum concentrations for prolonged periods and may offer an alternative to conventional intravenous antibiotic regimens. Oritavancin is not TGA-registered in Australia and is accessed as an unregistered medicine (for example, via SAS or clinical trials). It is approved in other jurisdictions, including the United States and European Union, for acute bacterial skin and skin structure infections. Prospective data in cardiac infections remain limited, and optimal dosing strategies, including the role of therapeutic drug monitoring, are uncertain. This multicentre, open-label pilot study will assess the feasibility, pharmacokinetics, safety, acceptability, and preliminary efficacy of oritavancin for gram-positive cardiac infections using both standard fixed dosing and TDM-guided dosing strategies. Findings will inform PK/PD modelling, the potential role of TDM, and the design of future larger-scale trials and models of care, including alternatives to prolonged inpatient intravenous therapy.

Начало: 01.07.2026 Край: 30.09.2028 Възраст: от 18 г.

Australia Kirby Institute NCT07550595

Предстои набиране

Real-time Engagement for Learning to Effectively Control Type 2 Diabetes

Diabetes Mellitus, Type 2 Lifestyle Hyperglycemia Physical Inactivity

This is a clinical trial that includes a run-in period, a 90 day micro-randomized trial, and a 90-day observational period. The goal of this study is to evaluate whether providing paired real time glycemic and health behavior data in a smartphone app leads to better glycemic control among adolescents and young adults with T2D. Glycemic control will be monitored using Continuous Glucose Monitors (CGM), and health behavior data will be collected via a Fitbit activity tracker and a research app (Healthmine). Participants will be prompted to view and reflect on glycemic trends and health behavior data (Fitbit data, logging of diet and medication adherence) during the 90-day micro-randomized trial period, then observed for ongoing use of the Healthmine app and engagement with CGM in the following 90-day observation period.

Начало: 01.07.2026 Край: 01.08.2029 Възраст: 16–24 г.

United States University of Pittsburgh NCT06375460

Предстои набиране Фаза 1

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

The purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1.

Начало: 30.06.2026 Край: 01.11.2033 Възраст: 18–75 г.

United States Genentech, Inc. NCT06984341

Предстои набиране Фаза 2

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

Chronic Kidney Disease

This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40

Начало: 30.06.2026 Край: 31.01.2028 Възраст: 18–75 г. Лечение

Australia, China Atom Therapeutics Co., Ltd NCT07323095

Предстои набиране

Pre-anesthetic Teleconsultations During Pregnancy

Pregnancy Anesthesia Satisfaction Telemedicine

Quality of teleconsultation in comparison to face-to-face consultation for pre anesthetic evaluation in pregnant persons before delivery will be evaluated. Quality is evaluated with a composite criterion comprising 7 elements required for security of anesthesia. Discordance between this composite criterion during the pre anesthesia visit the day of delivery and pre anesthesia consultation several weeks before delivery will be assessed.

Начало: 30.06.2026 Край: 01.06.2028 Възраст: от 18 г.

France University Hospital, Bordeaux NCT07542197

Предстои набиране Фаза 2

Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

Ischemic Stroke

Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain. However, even with this treatment, over half of the patients either pass away or are left with serious disabilities within three months. This is partly because, even in cases of a successful EVT, brain tissue damage continues to grow. Extent of brain damage is a major factor in how well a patient recovers. Studies in animals have shown that a drug called semaglutide might help protect the brain and improve recovery after a stroke. Semaglutide is currently used for the treatment of diabetes and obesity and is given as a weekly injection under the skin. The investigators are hoping to test whether giving semaglutide to stroke patients undergoing EVT can improve their recovery. A very large study at many hospitals is needed to answer this question. The investigators are starting with a smaller study to gain information on whether it is possible to perform a larger definitive one, and if so, how best to plan for it. In this first step the investigators will study 100 patients with stroke who are scheduled for EVT in approximately 10 stroke centers across Canada. These patients will be randomly divided (like flipping a coin) into two groups: one will receive weekly semaglutide injections for 12 weeks, while the other will not receive the drug. The investigators will track how many patients agree to participate, how many stay in the study, and how well they follow the treatment plan. The investigators will also monitor the patients' recovery, overall health, and any side effects from the treatment. These results will provide important information to plan the larger study with the goal of reducing death rates and long-term disability in stroke patients undergoing EVT.

Начало: 30.06.2026 Край: 30.06.2028 Възраст: от 18 г.

Population Health Research Institute NCT07511543

Предстои набиране Фаза 1

A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer

mCRC

This is a multicentre, randomized, double-blind, parallel-controlled Phase 1 clinical study designed to evaluate the pharmacokinetic (PK) similarity, efficacy, safety, and immunogenicity of HLX05-N compared with US-sourced ERBITUX® and EU-sourced ERBITUX® in participants with metastatic colorectal cancer (mCRC) with wild-type KRAS/NRAS and no BRAF V600E mutation. Approximately 387 participants will be randomized in a 1:1:1 ratio to receive HLX05-N, US-ERBITUX®, or EU-ERBITUX®. Randomization will be stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1) and sex (male vs. female). During the treatment period, participants will receive study treatment in combination with mFOLFOX6 chemotherapy. For the first 3 treatment cycles, participants will receive HLX05-N or US-/EU-ERBITUX® plus chemotherapy according to randomized assignment. After completion of the initial 3 cycles, participants originally assigned to the US-ERBITUX® or EU-ERBITUX® arms will switch, in a blinded manner, to HLX05-N 250 mg/m² administered in combination with chemotherapy on Day 1 of each cycle. Study treatment will continue until investigator-assessed disease progression, death, initiation of new anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent, study termination, or 1 year after randomization, whichever occurs first. For participants with disease response or stable disease after 12 cycles of treatment, oxaliplatin may be discontinued, and maintenance therapy with cetuximab in combination with leucovorin and 5-fluorouracil may continue. Participants who continue to benefit from treatment after 1 year following randomization may receive subsequent therapy according to local clinical practice. PK and anti-drug antibody (ADA) samples will be collected from all participants to assess PK characteristics and immunogenicity. An end-of-treatment visit will be performed within 7 days after treatment discontinuation. Safety follow-up will be conducted 30 days after the last dose, with an additional telephone safety follow-up at 12 weeks after the last dose. Survival follow-up will continue for up to 1 year after randomization.

Начало: 30.06.2026 Край: 30.04.2028 Възраст: 18–75 г.

Shanghai Henlius Biotech NCT07543471

Предстои набиране

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

Chagas Disease

This is an observational study in which data from women with Chagas disease who will take or have already taken nifurtimox during pregnancy and the impact on their babies are studied. Chagas disease is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi. This parasite is mainly spread by insects called triatomine bug. If Chagas disease is left untreated, it can later cause e.g. serious heart and digestive problems. Nifurtimox has been used for more than 50 years to treat Chagas disease in children and adults. It is not recommended to be used during pregnancy as data from animal studies indicate that it may harm the baby. Currently, there are not enough data to know if this is also the case in humans. In this study, researchers want to collect data on the safety of nifurtimox use in pregnant women. To do this, researchers will collect the following information: * Birth defects (abnormal and problematic structures or functions, a child is born with) * Pregnancy outcomes (like live birth, preterm birth, still birth/death of the unborn baby, miscarriage, or abortion) * Certain health problems of the child up to 12 months of age * Certain health problems of the women experienced during pregnancy The data will be collected from different sources including telephone calls with the women or their doctor, CRFs (case reprt forms) or from medical records The researchers will compare the proportion of children with birth defects, pregnancy outcomes or certain health problems of the child or the women during pregnancy with available data on these outcomes in the general population. The study will run for approximately 10 years.

Начало: 30.06.2026 Край: 31.01.2032

Argentina, Bolivia, Chile +9 Bayer NCT05477953

1 … 152 153 154 155 156 … 240